Anti-Rheumatic Drugs - Israel | Statista Market Forecast

In Israel, the Anti-Rheumatic Drugs market is anticipated to witness a significant increase in revenue, with projections indicating a staggering amount of US$78.09m in 2024.
Moreover, experts predict an annual growth rate of 0.74%, leading to a market volume of US$81.04m by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching a remarkable US$34.70bn in 2024.
Israel is at the forefront of research and development in the field of Anti-Rheumatic Drugs, pioneering innovative treatments for patients.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

Israel, a small country in the Middle East, has a growing Anti-Rheumatic Drugs market that is driven by various factors.

Customer preferences: Patients in Israel suffering from rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis have a high demand for Anti-Rheumatic Drugs. They prefer drugs that have fewer side effects and can provide long-term relief from pain and inflammation. Moreover, they prefer drugs that can be self-administered at home, reducing the need for frequent hospital visits.

Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Israel is the increasing use of biologic drugs. These drugs are highly effective in reducing inflammation and pain, with fewer side effects compared to traditional disease-modifying antirheumatic drugs (DMARDs). Biologics are also preferred due to their long-term benefits and self-administration. Another trend is the introduction of biosimilars, which are cheaper alternatives to biologics. Biosimilars have the same efficacy and safety profile as biologics, but at a lower cost. This has increased the affordability of Anti-Rheumatic Drugs for patients in Israel.

Local special circumstances: Israel has a high prevalence of rheumatic diseases, with about 2.5% of the population suffering from rheumatoid arthritis alone. This has led to a high demand for Anti-Rheumatic Drugs in the country. Moreover, Israel has a strong healthcare system that provides universal coverage for its citizens. This has increased the accessibility of Anti-Rheumatic Drugs to patients, irrespective of their socio-economic status.

Underlying macroeconomic factors: Israel has a strong pharmaceutical industry that is focused on innovation and development of new drugs. This has led to the introduction of new Anti-Rheumatic Drugs in the market, providing patients with more treatment options. Moreover, Israel has a high level of healthcare expenditure, with the government spending about 7.5% of its GDP on healthcare. This has increased the affordability of Anti-Rheumatic Drugs for patients in the country. Additionally, Israel has a high level of research and development in the healthcare sector, which has led to the discovery of new drugs and therapies for rheumatic diseases.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.